346 related articles for article (PubMed ID: 35522218)
1. Altered glycosylation in pancreatic cancer and beyond.
Lumibao JC; Tremblay JR; Hsu J; Engle DD
J Exp Med; 2022 Jun; 219(6):. PubMed ID: 35522218
[TBL] [Abstract][Full Text] [Related]
2. Role of tumor cell sialylation in pancreatic cancer progression.
Marciel MP; Haldar B; Hwang J; Bhalerao N; Bellis SL
Adv Cancer Res; 2023; 157():123-155. PubMed ID: 36725107
[TBL] [Abstract][Full Text] [Related]
3. COSMC knockdown mediated aberrant O-glycosylation promotes oncogenic properties in pancreatic cancer.
Hofmann BT; Schlüter L; Lange P; Mercanoglu B; Ewald F; Fölster A; Picksak AS; Harder S; El Gammal AT; Grupp K; Güngör C; Drenckhan A; Schlüter H; Wagener C; Izbicki JR; Jücker M; Bockhorn M; Wolters-Eisfeld G
Mol Cancer; 2015 May; 14():109. PubMed ID: 26021314
[TBL] [Abstract][Full Text] [Related]
4. Glycoproteins and glycoproteomics in pancreatic cancer.
Pan S; Brentnall TA; Chen R
World J Gastroenterol; 2016 Nov; 22(42):9288-9299. PubMed ID: 27895417
[TBL] [Abstract][Full Text] [Related]
5. The role of N-glycosylation modification in the pathogenesis of liver cancer.
Hu M; Zhang R; Yang J; Zhao C; Liu W; Huang Y; Lyu H; Xiao S; Guo D; Zhou C; Tang J
Cell Death Dis; 2023 Mar; 14(3):222. PubMed ID: 36990999
[TBL] [Abstract][Full Text] [Related]
6. T-cell programming in pancreatic adenocarcinoma: a review.
Seo YD; Pillarisetty VG
Cancer Gene Ther; 2017 Mar; 24(3):106-113. PubMed ID: 27910859
[TBL] [Abstract][Full Text] [Related]
7. Profiling of different pancreatic cancer cells used as models for metastatic behaviour shows large variation in their N-glycosylation.
Holst S; Belo AI; Giovannetti E; van Die I; Wuhrer M
Sci Rep; 2017 Nov; 7(1):16623. PubMed ID: 29192278
[TBL] [Abstract][Full Text] [Related]
8. Stroma and pancreatic ductal adenocarcinoma: an interaction loop.
Luo G; Long J; Zhang B; Liu C; Xu J; Ni Q; Yu X
Biochim Biophys Acta; 2012 Aug; 1826(1):170-8. PubMed ID: 22521638
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the glyco-code in pancreatic ductal adenocarcinoma identifies glycan-mediated immune regulatory circuits.
Rodriguez E; Boelaars K; Brown K; Madunić K; van Ee T; Dijk F; Verheij J; Li RJE; Schetters STT; Meijer LL; Le Large TYS; Driehuis E; Clevers H; Bruijns SCM; O'Toole T; van Vliet SJ; Bijlsma MF; Wuhrer M; Kazemier G; Giovannetti E; Garcia-Vallejo JJ; van Kooyk Y
Commun Biol; 2022 Jan; 5(1):41. PubMed ID: 35017635
[TBL] [Abstract][Full Text] [Related]
10. The Landscape of Pancreatic Cancer Therapeutic Resistance Mechanisms.
Chand S; O'Hayer K; Blanco FF; Winter JM; Brody JR
Int J Biol Sci; 2016; 12(3):273-82. PubMed ID: 26929734
[TBL] [Abstract][Full Text] [Related]
11. Aberrant expression of mucin core proteins and o-linked glycans associated with progression of pancreatic cancer.
Remmers N; Anderson JM; Linde EM; DiMaio DJ; Lazenby AJ; Wandall HH; Mandel U; Clausen H; Yu F; Hollingsworth MA
Clin Cancer Res; 2013 Apr; 19(8):1981-93. PubMed ID: 23446997
[TBL] [Abstract][Full Text] [Related]
12. A rapid in vivo screen for pancreatic ductal adenocarcinoma therapeutics.
Ocal O; Pashkov V; Kollipara RK; Zolghadri Y; Cruz VH; Hale MA; Heath BR; Artyukhin AB; Christie AL; Tsoulfas P; Lorens JB; Swift GH; Brekken RA; Wilkie TM
Dis Model Mech; 2015 Oct; 8(10):1201-11. PubMed ID: 26438693
[TBL] [Abstract][Full Text] [Related]
13. Multivariate data analysis for the detection of human alpha-acid glycoprotein aberrant glycosylation in pancreatic ductal adenocarcinoma.
Mancera-Arteu M; Giménez E; Balmaña M; Barrabés S; Albiol-Quer M; Fort E; Peracaula R; Sanz-Nebot V
J Proteomics; 2019 Mar; 195():76-87. PubMed ID: 30641231
[TBL] [Abstract][Full Text] [Related]
14. Metabolic plasticity in heterogeneous pancreatic ductal adenocarcinoma.
Liang C; Qin Y; Zhang B; Ji S; Shi S; Xu W; Liu J; Xiang J; Liang D; Hu Q; Ni Q; Xu J; Yu X
Biochim Biophys Acta; 2016 Dec; 1866(2):177-188. PubMed ID: 27600832
[TBL] [Abstract][Full Text] [Related]
15. AXL Is a Key Factor for Cell Plasticity and Promotes Metastasis in Pancreatic Cancer.
Du W; Phinney NZ; Huang H; Wang Z; Westcott J; Toombs JE; Zhang Y; Beg MS; Wilkie TM; Lorens JB; Brekken RA
Mol Cancer Res; 2021 Aug; 19(8):1412-1421. PubMed ID: 33811159
[TBL] [Abstract][Full Text] [Related]
16. Quantitative glycoproteomics analysis reveals changes in N-glycosylation level associated with pancreatic ductal adenocarcinoma.
Pan S; Chen R; Tamura Y; Crispin DA; Lai LA; May DH; McIntosh MW; Goodlett DR; Brentnall TA
J Proteome Res; 2014 Mar; 13(3):1293-306. PubMed ID: 24471499
[TBL] [Abstract][Full Text] [Related]
17. Carcinogenesis of Pancreatic Ductal Adenocarcinoma.
Storz P; Crawford HC
Gastroenterology; 2020 Jun; 158(8):2072-2081. PubMed ID: 32199881
[TBL] [Abstract][Full Text] [Related]
18. The plasticity of pancreatic cancer metabolism in tumor progression and therapeutic resistance.
Biancur DE; Kimmelman AC
Biochim Biophys Acta Rev Cancer; 2018 Aug; 1870(1):67-75. PubMed ID: 29702208
[TBL] [Abstract][Full Text] [Related]
19. Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor-stroma crosstalk.
Orozco CA; Martinez-Bosch N; Guerrero PE; Vinaixa J; Dalotto-Moreno T; Iglesias M; Moreno M; Djurec M; Poirier F; Gabius HJ; Fernandez-Zapico ME; Hwang RF; Guerra C; Rabinovich GA; Navarro P
Proc Natl Acad Sci U S A; 2018 Apr; 115(16):E3769-E3778. PubMed ID: 29615514
[TBL] [Abstract][Full Text] [Related]
20. Microfibril associated protein 4 (MFAP4) is a carrier of the tumor associated carbohydrate sialyl-Lewis x (sLe
Guerrero PE; Duran A; Ortiz MR; Castro E; Garcia-Velasco A; Llop E; Peracaula R
J Proteomics; 2021 Jan; 231():104004. PubMed ID: 33038510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
